Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04924114 | A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) | PHASE1 | COMPLETED | 57 | — | — | Oct 14, 2021 | Jul 15, 2024 | Aug 29, 2025 | 17 | United States, Georgia +6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to thestudy intervention
| Arm | Type | Description |
|---|---|---|
| MK-6194 Low Dose - Interval 1 (Less Frequent) | EXPERIMENTAL | Participants received low dose of MK-6194 at specified less frequent intervals |
| MK-6194 Medium Dose- Interval 2 (More Frequent) | EXPERIMENTAL | Participants received medium dose of MK-6194 at specified more frequent intervals |
| MK-6194 High Dose- Interval 2 (More Frequent) | EXPERIMENTAL | Participants received high dose of MK-6194 at specified more frequent intervals |
| MK-6194 High Dose- Interval 1 (Less Frequent) | EXPERIMENTAL | Participants received high dose MK-6194 at specified less frequent intervals |
| Placebo | PLACEBO_COMPARATOR | Participants received MK- 6194-matching placebo via subcutaneous injection, administered either at interval 1 or interval 2 |
| Name | Type | Description |
|---|---|---|
| MK-6194 | DRUG | Subcutaneous injection |
| MK-6194-matching placebo | DRUG | Subcutaneous injection |
Inclusion Criteria: * Diagnosis of UC at least 3 months prior to screening. * Mildly to severely active UC. * Inadequate response, loss of response, or intolerance to at least 1 prior conventional therapy, and no more than 2 prior advanced therapies. * Participants at risk for colorectal cancer mus...